OBJECTIVE: To probe into the effects of lialulutide in elderly patients with glucose and lipid metabolic disorders induced by oral antipsychotics. METHODS: A total of 100 elderly patients with mental disorders who were given olanzapine or clozapine from Dec. 2018 to Dec. 2019 in outpatient and inpatient departments of Emergency General Hospital were randomly divided into the study group and the control group

with 50 cases in each group.Patients in the study group were treated with liraglutide for 16 weeks

while the control group received lifestyle intervention. Changes in body weight

waist circumference

blood pressure

blood glucose

pancreatic β function

total cholesterol and low density lipoprotein-cholesterol levels before and after treatment in two groups were compared.RESULTS: After 16 weeks of liraglutide treatment

the weight[（-5. 4 ± 0. 9） kg

P < 0. 001]

waist circumference[（-4. 9 ± 0. 7） cm

P = 0. 002]

systolic blood pressure[（-4. 8 ± 2. 0） mm Hg（ 1 mm Hg = 0. 133 kPa）

P =0. 004]

total cholesterol [（-0. 51 ± 0. 09） mmol/L

P = 0. 02 ]

low density lipoprotein-cholesterol [（-0. 39 ±0. 08） mmol/L

P = 0. 015]

and fasting blood glucose[（-1. 4 ± 0. 8） mmol/L

P = 0. 020]in the study group were significantly lower than before treatment

and were significantly lower than those in the control group

the differences were statistically significant（ P < 0. 05）. Compared with before treatment

the pancreatic β-cell function indicators（ 23. 43 ± 3. 18

P < 0. 001） of the study group increased significantly

and the insulin resistance indicators（-1. 46 ±0. 34

P < 0. 001） decreased significantly. Compared with the control group

the pancreatic β function of the study group was significantly improved

and the difference was statistically significant（ P < 0. 05）. CONCLUSIONS:Liranutide can effectively resist glucose and lipid metabolic disorders induced by oral antipsychotics

improve pancreatic β function and insulin resistance

significantly reduce body weight and blood glucose levels

and delay the occurrence and development of type 2 diabetes in elderly patients with mental disorders.